<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39337407</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Disulfide Bond Engineering of Soluble ACE2 for Thermal Stability Enhancement.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9919</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms25189919</ELocationID><Abstract><AbstractText>Although the primary pandemic of SARS-CoV-2 is over, there are concerns about the resurgence of the next wave of related viruses, including a wide range of variant viruses. The soluble ACE2 (sACE2) inhibits the SARS-CoV-2 spike protein ACE2 interaction and has potential as a variant-independent therapeutic against SARS-CoV-2. Here, we introduce novel disulfide bonds in the wild-type sACE2-Fc by structure-guided mutagenesis, aiming to improve its stability. The stability of each mutant was assessed by a thermal shift assay to screen mutants with increased thermal stability. As a result, we identified a mutant sACE2-Fc with a significantly increased melting temperature. X-ray crystal structure determination of the sACE2 mutant confirmed the correct formation of the designed disulfide bond, and there were no significant structural disturbances. We also proved that the thermostable sACE2-Fc preserved the spike protein binding affinity comparable to the wild-type sACE2-Fc in both molecular and cellular environments, suggesting its therapeutic potential.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yoon Soo</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, College of Engineering, Hanyang University, Seoul 04673, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Myeongbin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, College of Engineering, Hanyang University, Seoul 04673, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hye Min</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, College of Engineering, Hanyang University, Seoul 04673, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyun Jin</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, College of Engineering, Hanyang University, Seoul 04673, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Seong Eon</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, College of Engineering, Hanyang University, Seoul 04673, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004220">Disulfides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="Y">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004220" MajorTopicYN="Y">Disulfides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055550" MajorTopicYN="Y">Protein Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015202" MajorTopicYN="N">Protein Engineering</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">disulfide bond</Keyword><Keyword MajorTopicYN="N">soluble ACE2</Keyword><Keyword MajorTopicYN="N">thermal stability enhancement</Keyword><Keyword MajorTopicYN="N">variant-independent therapeutics</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39337407</ArticleId><ArticleId IdType="pmc">PMC11432317</ArticleId><ArticleId IdType="doi">10.3390/ijms25189919</ArticleId><ArticleId IdType="pii">ijms25189919</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Badawi S., Ali B.R. ACE2 Nascence, trafficking, and SARS-CoV-2 pathogenesis: The saga continues. Hum. Genom. 2021;15:8. doi: 10.1186/s40246-021-00304-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40246-021-00304-9</ArticleId><ArticleId IdType="pmc">PMC7844112</ArticleId><ArticleId IdType="pubmed">33514423</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I., Cooper M.E., Haagmans B.L., Hooper N.M., Korstanje R., Osterhaus A.D., Timens W., Turner A.J., Navis G., van Goor H. The emerging role of ACE2 in physiology and disease. J. Pathol. 2007;212:1–11. doi: 10.1002/path.2162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2162</ArticleId><ArticleId IdType="pmc">PMC7167724</ArticleId><ArticleId IdType="pubmed">17464936</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgonje A.R., Abdulle A.E., Timens W., Hillebrands J.L., Navis G.J., Gordijn S.J., Bolling M.C., Dijkstra G., Voors A.A., Osterhaus A.D., et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19) J. Pathol. 2020;251:228–248. doi: 10.1002/path.5471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.5471</ArticleId><ArticleId IdType="pmc">PMC7276767</ArticleId><ArticleId IdType="pubmed">32418199</ArticleId></ArticleIdList></Reference><Reference><Citation>Bank S., De S.K., Bankura B., Maiti S., Das M., Khan G.A. ACE/ACE2 balance might be instrumental to explain the certain comorbidities leading to severe COVID-19 cases. Biosci. Rep. 2021;41:BSR20202014. doi: 10.1042/BSR20202014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20202014</ArticleId><ArticleId IdType="pmc">PMC7856554</ArticleId><ArticleId IdType="pubmed">33442728</ArticleId></ArticleIdList></Reference><Reference><Citation>Wysocki J., Ye M., Hassler L., Gupta A.K., Wang Y., Nicoleascu V., Randall G., Wertheim J.A., Batlle D. A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids. J. Am. Soc. Nephrol. 2021;32:795–803. doi: 10.1681/ASN.2020101537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2020101537</ArticleId><ArticleId IdType="pmc">PMC8017551</ArticleId><ArticleId IdType="pubmed">33526471</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwanaga N., Cooper L., Rong L., Maness N.J., Beddingfield B., Qin Z., Crabtree J., Tripp R.A., Yang H., Blair R., et al. ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2. iScience. 2022;25:103670. doi: 10.1016/j.isci.2021.103670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103670</ArticleId><ArticleId IdType="pmc">PMC8686446</ArticleId><ArticleId IdType="pubmed">34957381</ArticleId></ArticleIdList></Reference><Reference><Citation>Du L., He Y., Zhou Y., Liu S., Zheng B.J., Jiang S. The spike protein of SARS-CoV—A target for vaccine and therapeutic development. Nat. Rev. Microbiol. 2009;7:226–236. doi: 10.1038/nrmicro2090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2090</ArticleId><ArticleId IdType="pmc">PMC2750777</ArticleId><ArticleId IdType="pubmed">19198616</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker S.C. Coronaviruses: From common colds to severe acute respiratory syndrome. Pediatr. Infect. Dis. J. 2004;23:1049–1050. doi: 10.1097/01.inf.0000145815.70485.f7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000145815.70485.f7</ArticleId><ArticleId IdType="pubmed">15545861</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteil V., Kwon H., Prado P., Hagelkruys A., Wimmer R.A., Stahl M., Leopoldi A., Garreta E., Hurtado Del Pozo C., Prosper F., et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020;181:905–913.e7. doi: 10.1016/j.cell.2020.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.004</ArticleId><ArticleId IdType="pmc">PMC7181998</ArticleId><ArticleId IdType="pubmed">32333836</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwanaga N., Cooper L., Rong L., Beddingfield B., Crabtree J., Tripp R.A., Qin X., Kolls J.K. Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2. bioRxiv. 2020 doi: 10.1101/2020.06.15.152157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.15.152157</ArticleId></ArticleIdList></Reference><Reference><Citation>Renzi F., Seamann A., Ganguly K., Pandey K., Byrareddy S.N., Batra S., Kumar S., Ghersi D. Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus. ACS Pharmacol. Transl. Sci. 2023;6:857–867. doi: 10.1021/acsptsci.2c00180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.2c00180</ArticleId><ArticleId IdType="pmc">PMC10262318</ArticleId><ArticleId IdType="pubmed">37325447</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs E., Rudnik-Jansen I., Dinesen A., Selnihhin D., Mandrup O.A., Thiam K., Kjems J., Pedersen F.S., Howard K.A. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension. Acta Biomater. 2022;153:411–418. doi: 10.1016/j.actbio.2022.09.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2022.09.048</ArticleId><ArticleId IdType="pmc">PMC9508356</ArticleId><ArticleId IdType="pubmed">36162760</ArticleId></ArticleIdList></Reference><Reference><Citation>Havranek B., Lindsey G.W., Higuchi Y., Itoh Y., Suzuki T., Okamoto T., Hoshino A., Procko E., Islam S.M. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo. Commun. Biol. 2023;6:513. doi: 10.1038/s42003-023-04860-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-023-04860-9</ArticleId><ArticleId IdType="pmc">PMC10177734</ArticleId><ArticleId IdType="pubmed">37173421</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Narayanan K.K., Cooper L., Chan K.K., Skeeters S.S., Devlin C.A., Aguhob A., Shirley K., Rong L., Rehman J., et al. An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2. EMBO Mol. Med. 2022;14:e16109. doi: 10.15252/emmm.202216109.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202216109</ArticleId><ArticleId IdType="pmc">PMC9539395</ArticleId><ArticleId IdType="pubmed">36094679</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Qian K., Zhang S., Fu W., Zhao J., Lei C., Hu S. Engineered soluble ACE2 receptor: Responding to change with change. Front. Immunol. 2022;13:1084331. doi: 10.3389/fimmu.2022.1084331.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1084331</ArticleId><ArticleId IdType="pmc">PMC9891289</ArticleId><ArticleId IdType="pubmed">36741399</ArticleId></ArticleIdList></Reference><Reference><Citation>Zekri L., Ruetalo N., Christie M., Walker C., Manz T., Rammensee H.G., Salih H.R., Schindler M., Jung G. Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro. Front. Immunol. 2023;14:1112505. doi: 10.3389/fimmu.2023.1112505.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1112505</ArticleId><ArticleId IdType="pmc">PMC10030959</ArticleId><ArticleId IdType="pubmed">36969164</ArticleId></ArticleIdList></Reference><Reference><Citation>Kegler A., Drewitz L., Arndt C., Daglar C., Rodrigues Loureiro L., Mitwasi N., Neuber C., Gonzalez Soto K.E., Bartsch T., Baraban L., et al. A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells. Front. Immunol. 2023;14:1204543. doi: 10.3389/fimmu.2023.1204543.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1204543</ArticleId><ArticleId IdType="pmc">PMC10293748</ArticleId><ArticleId IdType="pubmed">37383226</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu M., Yao W., Li Y., Ma D., Zhang Z., Wang H., Tang X., Wang Y., Li C., Cheng D., et al. Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection. Microbiol. Spectr. 2023;11:e0110023. doi: 10.1128/spectrum.01100-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.01100-23</ArticleId><ArticleId IdType="pmc">PMC10434153</ArticleId><ArticleId IdType="pubmed">37395664</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasgow A., Glasgow J., Limonta D., Solomon P., Lui I., Zhang Y., Nix M.A., Rettko N.J., Zha S., Yamin R., et al. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc. Natl. Acad. Sci. USA. 2020;117:28046–28055. doi: 10.1073/pnas.2016093117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2016093117</ArticleId><ArticleId IdType="pmc">PMC7668070</ArticleId><ArticleId IdType="pubmed">33093202</ArticleId></ArticleIdList></Reference><Reference><Citation>Arimori T., Ikemura N., Okamoto T., Takagi J., Standley D.M., Hoshino A. Engineering ACE2 decoy receptors to combat viral escapability. Trends Pharmacol. Sci. 2022;43:838–851. doi: 10.1016/j.tips.2022.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2022.06.011</ArticleId><ArticleId IdType="pmc">PMC9312672</ArticleId><ArticleId IdType="pubmed">35902282</ArticleId></ArticleIdList></Reference><Reference><Citation>Cianfarini C., Hassler L., Wysocki J., Hassan A., Nicolaescu V., Elli D., Gula H., Ibrahim A.M., Randall G., Henkin J., et al. Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant. Cells. 2024;13:203. doi: 10.3390/cells13030203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells13030203</ArticleId><ArticleId IdType="pmc">PMC10854654</ArticleId><ArticleId IdType="pubmed">38334597</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov P.V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N.I., Katzourakis A. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:361–379. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli A.M., Peacock T.P., Thorne L.G., Harvey W.T., Hughes J., Consortium C.-G.U., Peacock S.J., Barclay W.S., de Silva T.I., Towers G.J., et al. SARS-CoV-2 variant biology: Immune escape, transmission and fitness. Nat. Rev. Microbiol. 2023;21:162–177. doi: 10.1038/s41579-022-00841-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00841-7</ArticleId><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaidi A.K., Singh R.B. SARS-CoV-2 variant biology and immune evasion. Prog. Mol. Biol. Transl. Sci. 2024;202:45–66. doi: 10.1016/bs.pmbts.2023.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.pmbts.2023.11.007</ArticleId><ArticleId IdType="pubmed">38237990</ArticleId></ArticleIdList></Reference><Reference><Citation>Wysocki J., Ye M., Rodriguez E., Gonzalez-Pacheco F.R., Barrios C., Evora K., Schuster M., Loibner H., Brosnihan K.B., Ferrario C.M., et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: Prevention of angiotensin II-dependent hypertension. Hypertension. 2010;55:90–98. doi: 10.1161/HYPERTENSIONAHA.109.138420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.109.138420</ArticleId><ArticleId IdType="pmc">PMC2827767</ArticleId><ArticleId IdType="pubmed">19948988</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi Y., Suzuki T., Arimori T., Ikemura N., Mihara E., Kirita Y., Ohgitani E., Mazda O., Motooka D., Nakamura S., et al. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Nat. Commun. 2021;12:3802. doi: 10.1038/s41467-021-24013-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24013-y</ArticleId><ArticleId IdType="pmc">PMC8217473</ArticleId><ArticleId IdType="pubmed">34155214</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan M.C., Chan K.K., Procko E., Shukla D. Machine Learning Guided Design of High-Affinity ACE2 Decoys for SARS-CoV-2 Neutralization. J. Phys. Chem. B. 2023;127:1995–2001. doi: 10.1021/acs.jpcb.3c00469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpcb.3c00469</ArticleId><ArticleId IdType="pmc">PMC9999943</ArticleId><ArticleId IdType="pubmed">36827526</ArticleId></ArticleIdList></Reference><Reference><Citation>Towler P., Staker B., Prasad S.G., Menon S., Tang J., Parsons T., Ryan D., Fisher M., Williams D., Dales N.A., et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J. Biol. Chem. 2004;279:17996–18007. doi: 10.1074/jbc.M311191200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M311191200</ArticleId><ArticleId IdType="pmc">PMC7980034</ArticleId><ArticleId IdType="pubmed">14754895</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt B., Hogg P.J. Search for allosteric disulfide bonds in NMR structures. BMC Struct. Biol. 2007;7:49. doi: 10.1186/1472-6807-7-49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6807-7-49</ArticleId><ArticleId IdType="pmc">PMC1949407</ArticleId><ArticleId IdType="pubmed">17640393</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari M., Mekkaoui L., Ilca F.T., Akbar Z., Bughda R., Lamb K., Ward K., Parekh F., Karattil R., Allen C., et al. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants. J. Virol. 2021;95:e0068521. doi: 10.1128/JVI.00685-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00685-21</ArticleId><ArticleId IdType="pmc">PMC8432736</ArticleId><ArticleId IdType="pubmed">34287040</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A., Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221–224. doi: 10.1038/s41586-020-2179-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2179-y</ArticleId><ArticleId IdType="pmc">PMC7328981</ArticleId><ArticleId IdType="pubmed">32225175</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavodszky M., Chen C.W., Huang J.K., Zolkiewski M., Wen L., Krishnamoorthi R. Disulfide bond effects on protein stability: Designed variants of Cucurbita maxima trypsin inhibitor-V. Protein Sci. 2001;10:149–160. doi: 10.1110/ps.26801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1110/ps.26801</ArticleId><ArticleId IdType="pmc">PMC2249841</ArticleId><ArticleId IdType="pubmed">11266603</ArticleId></ArticleIdList></Reference><Reference><Citation>Futami J., Miyamoto A., Hagimoto A., Suzuki S., Futami M., Tada H. Evaluation of irreversible protein thermal inactivation caused by breakage of disulphide bonds using methanethiosulphonate. Sci. Rep. 2017;7:12471. doi: 10.1038/s41598-017-12748-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-12748-y</ArticleId><ArticleId IdType="pmc">PMC5622167</ArticleId><ArticleId IdType="pubmed">28963503</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. doi: 10.1126/science.abb2507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2507</ArticleId><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Teilum K., Olsen J.G., Kragelund B.B. Functional aspects of protein flexibility. Cell Mol. Life Sci. 2009;66:2231–2247. doi: 10.1007/s00018-009-0014-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-009-0014-6</ArticleId><ArticleId IdType="pmc">PMC11115794</ArticleId><ArticleId IdType="pubmed">19308324</ArticleId></ArticleIdList></Reference><Reference><Citation>Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–326. doi: 10.1016/S0076-6879(97)76066-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0076-6879(97)76066-X</ArticleId><ArticleId IdType="pubmed">27754618</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P., Lohkamp B., Scott W.G., Cowtan K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 2010;66:486–501. doi: 10.1107/S0907444910007493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444910007493</ArticleId><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebschner D., Afonine P.V., Baker M.L., Bunkoczi G., Chen V.B., Croll T.I., Hintze B., Hung L.W., Jain S., McCoy A.J., et al. Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 2019;75:861–877. doi: 10.1107/S2059798319011471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S2059798319011471</ArticleId><ArticleId IdType="pmc">PMC6778852</ArticleId><ArticleId IdType="pubmed">31588918</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>